Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer

Breast cancer (BC) is caused by epigenetic modifications and genetic heterogeneity and exhibits various histological feature. HER2+ (Human epidermal growth factor receptor 2) is a more aggressive type of breast cancer, diagnosis and prognosis are difficult for HER2+ BC. Anti-HER2+ inhibitors have be...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Desh Deepak, Lee, Hae-Jeung, Yadav, Dharmendra Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792097/
https://www.ncbi.nlm.nih.gov/pubmed/36578543
http://dx.doi.org/10.3389/fphar.2022.1089066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792097/
https://www.ncbi.nlm.nih.gov/pubmed/36578543
http://dx.doi.org/10.3389/fphar.2022.1089066

Ejemplares similares